Study #2023-0661
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended dose, evaluate PKs, PDs, safety, and activity of venetoclax in combination with oral decitabine/cedazuridine (ASTX727) in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
MD Anderson Study Status
Enrolling
Treatment Agent
ASTX727, Venetoclax
Description
To find a recommended dose of ASTX727 (cedazuridine/decitabine) in combination with venetoclax for pediatric patients with relapsed AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Amber Gibson
Department:
Pediatrics
For general questions about clinical trials:
1-833-997-2081
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.